Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.49 |
| ▸ | BRD2 | P25440 | 4/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739033 | 0.84 | BRD4 (0.48) | BRD4BRD2TRIM24BRD3BRDT | |
| SCHEMBL16739117 | 0.84 | BRD4 (0.64) | BRD4BRD2 | |
| SCHEMBL16738988 | 0.84 | BRD4 (0.49) | BRD4BRD2TRIM24BRD3BRDT | |
| SCHEMBL16738986 | 0.83 | BRD4 (0.60) | BRD4BRD2 | |
| Trifluoroacetic Acid SCHEMBL16739032 | 0.79 | BRD4 (0.61) | BRD4BRD2 | |
| SCHEMBL16738061 | 0.74 | BRD4 (0.64) | BRD4BRD2BRD3BRDT | |
| SCHEMBL18391632 | 0.73 | BRD4 (0.73) | BRD4BRD2 | |
| SCHEMBL16738899 | 0.73 | BRD4 (0.47) | BRD4BRD2TRIM24BRD3BRDT | |
| SCHEMBL16738923 | 0.71 | BRD4 (0.61) | BRD4BRD2 | |
| SCHEMBL16738979 | 0.71 | BRD4 (0.44) | BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | BRD4 1944/4885BRD2 1832/4885TRIM24 332/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | BRD4 376/4885BRD2 435/4885TRIM24 356/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | BRD4 922/4885BRD2 1310/4885TRIM24 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.